E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor

被引:66
作者
DiFeo, A.
Narla, G.
Camacho-Vanegas, O.
Nishio, H.
Rose, S. L.
Buller, R. E.
Friedman, S. L.
Walsh, M. J.
Martignetti, J. A.
机构
[1] Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA
[2] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA
[3] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA
[4] Univ Iowa Hosp & Clin, Div Gynecol Oncol, Iowa City, IA 52242 USA
[5] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA
关键词
KLF6; KLF6-SV1; E-cadherin; alternative splicing; ovarian cancer;
D O I
10.1038/sj.onc.1209611
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The tumor suppressor KLF6 is a member of the Kruppel-like family of transcription factors, which has been implicated in the pathogenesis of several human carcinomas. Uncovering the transcriptional targets relevant for its tumorigenic properties, including cellular proliferation and invasion, will be essential to understanding possible mechanisms by which KLF6 and its antagonistic splice form, KLF6-SV1, regulate this development. To begin de. ning possible metastatic-related pathways, we analysed the effect of KLF6 dysregulation on a recognized suppressor of cellular invasion, E-cadherin. Targeted KLF6 reduction in an ovarian cancer cell line, SKOV-3, resulted in a 50% reduction of E-cadherin expression (P < 0.01) and conversely, KLF6-SV1 silencing upregulated E-cadherin approximately fivefold (P < 0.0001). These changes resulted from KLF6 directly transactivating the E-cadherin promoter as demonstrated by luciferase promoter assay and chromatin immunoprecipitation (ChIP). KLF6-mediated changes in E-cadherin levels were accompanied by downstream changes in both the subcellular localization of beta-catenin and c-myc expression levels. Moreover, and consistent with these experimental findings, patient-derived epithelial ovarian tumors with low KLF6 and high KLF6-SV1 expression ratios had significantly decreased E-cadherin expression (P < 0.0001). These combined findings highlight the E-cadherin pathway as a novel and functionally important mediator by which changes in KLF6 and KLF6-SV1 can directly alter ovarian tumor invasion and metastasis.
引用
收藏
页码:6026 / 6031
页数:6
相关论文
共 34 条
[1]   Ligand-dependent activation of the farnesoid X-receptor directs arginine methylation of histone H3 by CARM1 [J].
Ananthanarayanan, M ;
Li, SD ;
Balasubramaniyan, N ;
Suchy, FJ ;
Walsh, MJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (52) :54348-54357
[2]   Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1 [J].
Benzeno, S ;
Narla, G ;
Allina, J ;
Cheng, GZ ;
Reeves, HL ;
Banck, MS ;
Odin, JA ;
Diehl, JA ;
Germain, D ;
Friedman, SL .
CANCER RESEARCH, 2004, 64 (11) :3885-3891
[3]   Human ovarian cancer of the surface epithelium [J].
Berchuck, A ;
Carney, M .
BIOCHEMICAL PHARMACOLOGY, 1997, 54 (05) :541-544
[4]   Kruppel-like factors: Three fingers in many pies [J].
Bieker, JJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (37) :34355-34358
[5]   Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer [J].
Black, AR ;
Black, JD ;
Azizkhan-Clifford, J .
JOURNAL OF CELLULAR PHYSIOLOGY, 2001, 188 (02) :143-160
[6]   Deletion, mutation, and loss of expression of KLF6 in human prostate cancer [J].
Chen, CS ;
Hyytinen, ER ;
Sun, XD ;
Helin, HJ ;
Koivisto, PA ;
Frierson, HF ;
Vessella, RL ;
Dong, JT .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (04) :1349-1354
[7]  
Chen Han-kui, 2002, Ai Zheng, V21, P1047
[8]   Genetic alterations of the KLF6 gene in gastric cancer [J].
Cho, YG ;
Kim, CJ ;
Park, CH ;
Yang, YM ;
Kim, SY ;
Nam, SW ;
Lee, SH ;
Yoo, NJ ;
Lee, JY ;
Park, WS .
ONCOGENE, 2005, 24 (28) :4588-4590
[9]   Autoregulation of E-cadherin expression by cadherin-cadherin interactions:: the roles of β-catenin signaling, Slug, and MAPK [J].
Conacci-Sorrell, M ;
Simcha, I ;
Ben-Yedidia, T ;
Blechman, J ;
Savagner, P ;
Ben-Ze'ev, A .
JOURNAL OF CELL BIOLOGY, 2003, 163 (04) :847-857
[10]  
DIFEO A, 2006, IN PRESS CLIN CANC R